Current NHS consultant posts held
Consultant Urological Surgeon in Aberdeen Royal Infirmary for the past 21 years
Retired from NHS on 31 December 2018
Pursuing private practice to reduce patient waiting times
Research interests
Benign Prostatic Enlargement
Lower urinary tract symptoms
Bladder Cancer and Urine Cytology
Haematuria
Vasectomy
Personal interests
Table Tennis
Tennis
Cycling
Swimming
Awards received
1993: Bard Silver Medal Award: "The shock wave characteristic in lithotripsy and its clinical applications", Harrogate 23rd June 1993. The Bard Silver Medal is the most prestigious award granted by the British Association of Urological Surgeons.
(Additional) Languages spoken
Publications
Factors affecting the incidence of postoperative wound infection. Mishriki SF et al J Hosp Infect. 1990; 16:223-30.
Ureteric stone management using a second generation lithotripter. Mishriki SF et al. Br J Urol. 1992; 69: 253-6.
Extracorporeal shock wave lithotripsy for renal calculi in children. Mishriki SF et al. Br J Urol. 1992; 69: 303-5.
Wound infection: the surgeon's responsibility. Mishriki SF et al. J Wound Care 1992; 1: 32-6.
Urological audit: The role for an aggressive approach to high grade superficial bladder tumours. Br J Urol. 1992; 70: 156-60.
Choosing a powerful lithotriptor. Mishriki SF et al. Br J Urol 1993; 71: 653-60.
Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. Mishriki SF et al. Urology 2008; 71: 13-16.
Improved quality of life and enhanced satisfaction after TURP: prospective 12-year follow-up study. Mishriki SF et al. Urology 2008; 72: 322-6; discussion 326-8.
Incidence of Recurrent Frank Haematuria and Urological Cancers: Prospective 6.9 years Follow-up. Mishriki SF et al.J Urol 2009; 182: 1294-8.
Partners agree that the treatment of LUTS reduces patients' bother and improves their quality of life: prospective 12 years follow-up study. Mishriki SF et al. WJU 2010; 28: 123-32.
TURP and Sex: Patient and Partner Prospective 12 years Follow-up Study. Mishriki SF et al. BJUI 2011; 109: 745-50.
Half of visible and half of recurrent visible hematuria cases have underlying pathology: prospective large cohort study with long-term followup. Mishriki SF et al. J Urol 2012;187:1561-5.
Half of Visible and Half of Recurrent Visible Hematuria Cases have Underlying Pathology: Prospective Large Cohort Study with Long-Term Follow-Up. Mishriki SF et al. J Urol. 2012;3-7.
Routine urine cytology has no role in hematuria investigations. Mishriki SF et al. J Urol. 2013 : 390-4
Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms: prospective 12-year follow-up study. Mishriki SF et al. Urology. 2013 ;81:390-4.
Visible haematuria in patients under 40 years – Prospective study with 3-11 years follow-up. Mishriki SF et al. J Urol 2013;189 :2012-3.
Sole editor of The Benign and Malignant Prostate. Nova Science Publishers, New York, Published December 2013.
